Skip to main content
. 2009 Dec;25(6):487–498. doi: 10.1089/jop.2009.0049

FIG. 2. .

FIG. 2. 

(A) Cellular accumulation of [14C] erythromycin (0.2 μCi/mL) by primary corneal epithelial cells (rPCEC) in the presence of a P-gp inhibitor (GF120918, 2 μM), MRP inhibitor (MK571, 50 μM), bimatoprost (B, 50 μM), latanoprost (L, 50 μM), and travoprost (T, 50 μM). Each data point represents mean ± SD (n = 4). ** Significant difference from control (P < 0.01). (B) Cellular accumulation of [14C] erythromycin (0.2 μCi/mL) by rPCEC in the presence of free acid forms of bimatoprost (BA, 100 μM), latanoprost (LA, 100 μM), and travoprost (TA, 100 μM). Each data point represents mean ± SD (n = 4). *Significant difference from control (P < 0.05).